Nektar to present rezpegaldesleukin Phase 2b results at Denver dermatology summit
Nektar Therapeutics (NASDAQ:NKTR) will present Phase 2b clinical data for rezpegaldesleukin at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, the company announced.










